Expected Moves

Fiscal Q3 2026 earnings update focusing on early FY27 budget forecasts and remaining cash runway.

Anticipated early interim data or enrollment milestone for the Phase 2 trial of PAI-1 inhibitor RS5614 in locally advanced non-small cell lung cancer.

Full year fiscal 2026 earnings report and guidance for FY27 capital requirements.

Topline safety and tolerability readout for Phase 1 trials of RS5441 in alopecia and RS8001 for PMS/menopausal disorder.